Literature DB >> 27987148

Generation of Immunostimulating 130 nm Protamine-RNA nanoparticles.

Marina Tusup1, Steve Pascolo2.   

Abstract

Nanoparticles of defined size can be easily obtained by simply mixing Protamine, a pharmaceutical drug that is used to neutralize heparin after surgery, and RNA in the form of oligonucleotides or messenger RNA. Depending on the concentrations of the two reagents and their salt contents, homogenous nanoparticles with a mean diameter of 50 to more than 1000 nm can spontaneously be generated. RNA is a danger signal because it is an agonist of for example TLR-3, -7, and -8; therefore, Protamine-RNA nanoparticles are immunostimulating. We and others have shown in vitro that nanoparticle size and interferon-alpha production by human peripheral blood mononuclear cells (PBMCs) are inversely correlated. Conversely, nanoparticle size and TNF-alpha production by PBMCs are positively correlated (Rettig et al., Blood 115:4533-4541, 2010). Particles of less than 450 nm are most frequently used for research and clinical applications because they are very stable, remain polydispersed and induce interferon-alpha proteins, which are a natural antiviral and anticancer protein family with 12 members in humans. Herein, we describe a method to generate 130 nm nanoparticles as well as some of their physical and biological characteristics.

Entities:  

Keywords:  Interferon-alpha; Nanoparticles; Protamine; RNA; TNF-alpha; Toll like receptor

Mesh:

Substances:

Year:  2017        PMID: 27987148     DOI: 10.1007/978-1-4939-6481-9_9

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  6 in total

1.  Epitranscriptomics modifier pentostatin indirectly triggers Toll-like receptor 3 and can enhance immune infiltration in tumors.

Authors:  Marina Tusup; Thomas M Kündig; Steve Pascolo
Journal:  Mol Ther       Date:  2021-09-24       Impact factor: 11.454

Review 2.  Protamine-Based Strategies for RNA Transfection.

Authors:  Natalia Teresa Jarzebska; Mark Mellett; Julia Frei; Thomas M Kündig; Steve Pascolo
Journal:  Pharmaceutics       Date:  2021-06-14       Impact factor: 6.321

Review 3.  Establishing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens.

Authors:  Cristina Poveda; Amadeo B Biter; Maria Elena Bottazzi; Ulrich Strych
Journal:  Vaccines (Basel)       Date:  2019-09-27

Review 4.  mRNA vaccines in the prevention and treatment of diseases.

Authors:  Yangzhuo Gu; Jiangyao Duan; Na Yang; Yuxin Yang; Xing Zhao
Journal:  MedComm (2020)       Date:  2022-08-25

5.  Functional differences between protamine preparations for the transfection of mRNA.

Authors:  Natalia Teresa Jarzebska; Severin Lauchli; Christoph Iselin; Lars E French; Pal Johansen; Emmanuella Guenova; Thomas M Kündig; Steve Pascolo
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

6.  Lipofection with Synthetic mRNA as a Simple Method for T-Cell Immunomonitoring.

Authors:  Natalia Teresa Jarzebska; Julia Frei; Severin Lauchli; Lars E French; Emmanuella Guenova; Cécile Gouttefangeas; Thomas M Kündig; Mark Mellett; Steve Pascolo
Journal:  Viruses       Date:  2021-06-25       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.